Sorrento Therapeutics Releases Preclinical Data from STI-1499 and STI-2020 Demonstrating Potent Neutralizing Antibodies Against SARS-CoV-2

Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2

  • In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.
  • Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian golden hamsters.
  • At day 5, STI-2020 at 500 µg reduced virus load in hamster lungs to undetectable levels in 100% of animals tested, whereas STI-1499 at 2,000 µg reduced virus load below the . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.